<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03535610</url>
  </required_header>
  <id_info>
    <org_study_id>SC-ES_001</org_study_id>
    <nct_id>NCT03535610</nct_id>
  </id_info>
  <brief_title>Uterine Artery Embolization With Microspheres in Patients With Leiomyoma.</brief_title>
  <acronym>EMBOSOFT I</acronym>
  <official_title>Uterine Artery Embolization With Microspheres in Patients With Leiomyoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scitech Produtos Medicos Ltda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scitech Produtos Medicos Ltda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the therapeutic response to uterine artery embolization in 30 patients with&#xD;
      leiomyoma using the microspheres Embosoft (Embosoft® - Scitech Medical).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Actual">May 20, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single-arm, open label study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uterine Volume Reduction</measure>
    <time_frame>6 months</time_frame>
    <description>Uterine Volume Reduction measured by MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibroid Reduction</measure>
    <time_frame>6 months</time_frame>
    <description>Fibroid Reduction measured by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Improvement</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of Life Improvement measured by UFS-QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian Function</measure>
    <time_frame>6 months</time_frame>
    <description>Ovarian Function measured by Anti-Mullerian Hormon dosage pre and post-procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Uterine Leiomyoma</condition>
  <arm_group>
    <arm_group_label>Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uterine Embolization with PVA Microspheres</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Uterine Embolization</intervention_name>
    <description>Uterine Embolization with PVA Microspheres</description>
    <arm_group_label>Embolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  female patients from 18 to 50 years old;&#xD;
&#xD;
          -  symptomatic uterine intramural leiomyomas or multiple symptomatic leiomyomas in the&#xD;
             presence of intramural;&#xD;
&#xD;
          -  patient agrees with study procedures;&#xD;
&#xD;
          -  patient signs the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  asymptomatic women;&#xD;
&#xD;
          -  isolated adenomyosis, pediculated subserous myoma, submucous leiomyoma (50% of uterine&#xD;
             cavity diameter), intraligamentous leiomyoma;&#xD;
&#xD;
          -  leiomyoma diameter higher than 10 cm;&#xD;
&#xD;
          -  leiomyoma above the umbilical scar;&#xD;
&#xD;
          -  endometrial neoplasia or hyperplasia or presence of any malignancy&#xD;
&#xD;
          -  pregnant or breast feeding women;&#xD;
&#xD;
          -  active vasculitis;&#xD;
&#xD;
          -  pelvic irradiation history;&#xD;
&#xD;
          -  uncontrolled coagulopathies;&#xD;
&#xD;
          -  renal insufficiency;&#xD;
&#xD;
          -  contrast allergy;&#xD;
&#xD;
          -  concomitant use of GnRH analogues.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female patients with Uterine Leiomyoma</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Certa Centro de Referência em Tratamentos Avançados</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01401-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Embolization</keyword>
  <keyword>Uterine Leiomyoma</keyword>
  <keyword>Embospheres</keyword>
  <keyword>Microspheres</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

